Logo image of NSPR

INSPIREMD INC (NSPR) Stock Price, Forecast & Analysis

USA - NASDAQ:NSPR - US45779A8466 - Common Stock

2.11 USD
-0.02 (-0.94%)
Last: 11/5/2025, 4:30:01 PM

NSPR Key Statistics, Chart & Performance

Key Statistics
Market Cap88.03M
Revenue(TTM)7.01M
Net Income(TTM)-41381000
Shares41.72M
Float30.08M
52 Week High3.8
52 Week Low1.99
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-0.84
PEN/A
Fwd PEN/A
Earnings (Next)03-10 2026-03-10/amc
IPO2013-04-12
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Supplies


NSPR short term performance overview.The bars show the price performance of NSPR in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -5 -10 -15

NSPR long term performance overview.The bars show the price performance of NSPR in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 20 40 60

The current stock price of NSPR is 2.11 USD. In the past month the price decreased by -13.35%. In the past year, price decreased by -7.46%.

INSPIREMD INC / NSPR Daily stock chart

NSPR Latest News, Press Relases and Analysis

NSPR Competitors/Peers

The largest stocks on the US markets in the "Health Care Supplies" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ALC ALCON INC 24.62 37.15B
COO COOPER COS INC/THE 17.13 13.69B
SOLV SOLVENTUM CORP 11.13 11.74B
ALGN ALIGN TECHNOLOGY INC 14.19 9.95B
BLCO BAUSCH + LOMB CORP 36.58 5.57B
MMSI MERIT MEDICAL SYSTEMS INC 23.42 5.16B
LNTH LANTHEUS HOLDINGS INC 8.96 3.89B
ICUI ICU MEDICAL INC 16.94 3.15B
XRAY DENTSPLY SIRONA INC 7.38 2.52B
HAE HAEMONETICS CORP/MASS 10.91 2.44B
UFPT UFP TECHNOLOGIES INC 26.32 1.81B
ESTA ESTABLISHMENT LABS HOLDINGS N/A 1.75B

About NSPR

Company Profile

NSPR logo image InspireMD, Inc. is medical device company, which engages in the development and commercialization of its proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The company is headquartered in Miami, Florida and currently employs 85 full-time employees. The company went IPO on 2013-04-12. The firm is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). The company markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. The company is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.

Company Info

INSPIREMD INC

6303 Waterford District Drive, Suite 215

Miami FLORIDA 6744832 US

CEO: Marvin Slosman

Employees: 86

NSPR Company Website

NSPR Investor Relations

Phone: 18887766804

INSPIREMD INC / NSPR FAQ

What does INSPIREMD INC do?

InspireMD, Inc. is medical device company, which engages in the development and commercialization of its proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The company is headquartered in Miami, Florida and currently employs 85 full-time employees. The company went IPO on 2013-04-12. The firm is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). The company markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. The company is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.


Can you provide the latest stock price for INSPIREMD INC?

The current stock price of NSPR is 2.11 USD. The price decreased by -0.94% in the last trading session.


Does NSPR stock pay dividends?

NSPR does not pay a dividend.


How is the ChartMill rating for INSPIREMD INC?

NSPR has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


Which stock exchange lists NSPR stock?

NSPR stock is listed on the Nasdaq exchange.


How is the market expecting NSPR stock to perform?

8 analysts have analysed NSPR and the average price target is 4.59 USD. This implies a price increase of 117.54% is expected in the next year compared to the current price of 2.11.


What is the outstanding short interest for INSPIREMD INC?

The outstanding short interest for INSPIREMD INC (NSPR) is 0.38% of its float.


NSPR Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

NSPR Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to NSPR. NSPR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

NSPR Financial Highlights

Over the last trailing twelve months NSPR reported a non-GAAP Earnings per Share(EPS) of -0.84. The EPS decreased by -12% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -124.11%
ROE -204.42%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-6.25%
Sales Q2Q%39.23%
EPS 1Y (TTM)-12%
Revenue 1Y (TTM)12.96%

NSPR Forecast & Estimates

8 analysts have analysed NSPR and the average price target is 4.59 USD. This implies a price increase of 117.54% is expected in the next year compared to the current price of 2.11.

For the next year, analysts expect an EPS growth of -12.46% and a revenue growth 7.09% for NSPR


Analysts
Analysts82.5
Price Target4.59 (117.54%)
EPS Next Y-12.46%
Revenue Next Year7.09%

NSPR Ownership

Ownership
Inst Owners35.44%
Ins Owners14.39%
Short Float %0.38%
Short Ratio1.24